ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO288

Prognostic Value of Soluble ST2 and Soluble LR11 on Mortality and Cardiovascular Events in Peritoneal Dialysis Patients

Session Information

Category: Dialysis

  • 703 Dialysis: Peritoneal Dialysis


  • Shin, Yoon soo, CHA Hospital Bundang, Gyeonggi-do, Korea (the Republic of)
  • Kim, Hyung Jong, Bundang CHA Medical Center, CHA University, Seongnam, GyeonGgi-Do, Korea (the Republic of)
  • Lee, Mi Jung, CHA Bundang Medical Center, CHA University College of Medicine, Seongnam, Seoul, Korea (the Republic of)
  • Lee, Jung eun, Yongin Severance Hospital, Yongin-si, Korea (the Republic of)

Because end-stage renal disease (ESRD) patients are at high risk of cardiovascular
(CV) disease, developing a biomarker for CV risk stratification has clinical
importance. Soluble form of suppression of tumorigenicity 2 (sST2) and soluble
low-density lipoprotein receptor relative with 11 ligand-binding repeats (sLR11) are
emerging CV biomarkers, however, to date, the prognostic value of those has not
been investigated in patients undergoing peritoneal dialysis (PD).


We determined serum sST2 and sLR11 concentrations using enzyme-linked
immunosorbent assay, and evaluated the association of those biomarkers with all cause
mortality and major adverse cardiac and cerebrovascular event (MACCE) in
74 prevalent PD patients.


The median (interquartile range) concentrations of sST2 and sLR11 were 70.9
(57.8-89.8) ng/mL and 15.2 (12.3-19.6) ng/mL, respectively. During a median
follow-up of 38.5 months, 13 (17.6%) patients died and MACCE was observed in
23 (31.3%) patients. When patients were dichotomized by the median value of
sST2 and sLR11, Kaplan-Meier analyses showed that higher sST2 group was
significantly associated with lower event-free survival rates (log-rank test;
P=0.002 for all-cause death; P=0.01 for MACCE). In multivariable Cox analyses,
higher sST2 was independent risk factor for all-cause mortality (per 1 standard
deviation [SD] increase; hazard ratio [HR]=1.947; 95% confidence interval
[CI]=1.124-3.371) and MACCE (per 1 SD increase; HR=1.647; 95% CI=1.079-
2.516). In contrast, sLR11 did not have a significant association with all-cause
mortality or MACCE. Furthermore, only sST2 provided a significant predictive value
for all-cause mortality (AUC=0.699; P=0.03).


sST2, not sLR11, was independently associated with greater risk of all-cause
mortality and CV outcome in prevalent PD patients. Additional studies are needed
to confirm these findings and examine underlying mechanism between new
biomarkers and CV disease in ESRD populations.